Bayer, J&J’s Xarelto Wins EU Backing for Expanded Use

Bayer AG and Johnson & Johnson won European backing to expand marketing of their blood-thinner Xarelto to a group of heart-disease patients that U.S. authorities have been reluctant to clear for use of the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.